Does Pantoprazole Increase Kidney Disease Risk?
This is a post hoc analysis of a randomized controlled trial: within the COMPASS trial, 17,598 participants were randomly assigned to pantoprazole (8,791) or placebo (8,807), and the authors went back to that randomized comparison to ask what the drug did to kidney function.
Dr. Kumar’s Take
Concerns about proton pump inhibitors and kidney damage have circulated for years, mostly on the strength of observational database studies, which can show an association without establishing that the drug is the cause. This analysis is a better place to look, because the pantoprazole versus placebo comparison was randomized. The kidney question itself was asked after the trial concluded, so I read it as strong evidence of a small effect rather than a final word. The size matters as much as the significance here: the difference in kidney filtration decline between the two groups was a fraction of a point per year. My practice does not change on one paper. I prescribe PPIs when there is a clear indication, and I stop them when there is not.
What the Research Shows
The authors used data from the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, registered as NCT01776424, which randomized 17,598 participants to pantoprazole or placebo. The primary kidney outcome was the rate of change in eGFR, the standard measure of kidney filtration, calculated from two measurements: one at randomization and one at enrollment into the open-label extension study that began when the trial ended.
Of the 17,598 randomized participants, 51% had an eGFR recorded at both time points and formed the analysis population. Their mean age was 67 years, 22% were female, and mean baseline eGFR was 75 ml/min per 1.73 m². The mean gap between the two eGFR measurements was 3.3 years.
Study Snapshot
- Design: post hoc analysis of a randomized controlled trial (COMPASS, NCT01776424)
- Randomization: 8,791 to pantoprazole, 8,807 to placebo
- Analysis population: the 51% of randomized participants with eGFR at both time points
- Mean age 67 years, 22% female, mean baseline eGFR 75 ml/min per 1.73 m²
- Mean follow-up between eGFR measures: 3.3 years
- Primary outcome: rate of eGFR change
- Secondary outcomes: incident chronic kidney disease, acute kidney injury, acute nephritis, nephrotic syndrome
Results in Real Numbers
Kidney filtration declined in both groups over the roughly 3.3 years between measurements, which is expected in a population with this average age.
- Placebo: eGFR fell by 1.41 ml/min per 1.73 m² per year
- Pantoprazole: eGFR fell by 1.64 ml/min per 1.73 m² per year
In adjusted analyses, pantoprazole produced a 0.27 ml/min per 1.73 m² per year greater decline in eGFR, with a 95% confidence interval of 0.11 to 0.43. Because that interval does not cross zero, the difference is statistically significant.
The secondary outcomes did not reach statistical significance. For new-onset chronic kidney disease, defined as an eGFR below 60 ml/min per 1.73 m², pantoprazole was associated with an 11% relative increase in odds, but the confidence interval ran from a 2% reduction to a 25% increase, so this result is compatible with no effect. For acute kidney injury, pantoprazole was associated with an 11% relative reduction in odds, with a confidence interval spanning a 35% reduction to a 21% increase, again compatible with no effect. Across the whole trial there were five nephrotic syndrome outcomes and one event of acute nephritis, too few to draw any conclusion from.
Safety, Limits, and Caveats
The kidney question was asked after the trial had finished, not built into its design from the start, and the analysis rests on two eGFR measurements per person rather than a series tracked over time. Only 51% of randomized participants had both measurements available, so half the trial population could not be included.
The absolute effect is small. A difference of 0.27 ml/min per 1.73 m² per year, in a group starting at a mean eGFR of 75, is a real and statistically significant signal, but it is not the kind of drop that would move most individual patients into kidney disease over a few years. That is consistent with the neutral result on incident chronic kidney disease. The authors themselves conclude that additional studies are needed to determine the effect of proton pump inhibitors on people at higher risk of adverse kidney outcomes, which is the group this trial cannot speak to well.
One more point of interpretation: eGFR is estimated from creatinine, so anything that changes how the kidney handles creatinine changes the estimate without necessarily changing kidney function itself. A shift in measured eGFR on a PPI deserves interpretation rather than reflex alarm.
Practical Takeaways
- The randomized comparison found a real but small acceleration in kidney filtration decline on pantoprazole: 1.64 versus 1.41 ml/min per 1.73 m² per year
- Rates of new chronic kidney disease and acute kidney injury were not significantly different between pantoprazole and placebo
- This paper tested pantoprazole specifically, so extending the finding to every drug in the class is an assumption
- People already at higher risk of kidney problems were not the focus here, and the authors call for further study in that group
- Continue monitoring kidney function in patients at higher risk, whichever PPI they take
- Prescribe PPIs for clear indications and reassess whether the indication still holds
Related Studies and Research
- Acute Interstitial Nephritis Due to Proton Pump Inhibitors
- Pharmacology of Proton Pump Inhibitors
- Trends in Use of Proton Pump Inhibitors Among Adults in the United States
- Use of Proton Pump Inhibitors and Risk of Iron Deficiency: Population-Based Study
- Episode 25: The Great GERD Mistake - How Medicine Made Heartburn Worse and How to Fix It
FAQs
Does this paper apply to all PPIs?
It tested pantoprazole. Extending the conclusion to every drug in the class is an assumption, not something this paper establishes.
How big is the effect on my kidneys?
In the trial, the pantoprazole group lost 1.64 ml/min per 1.73 m² of filtration per year and the placebo group lost 1.41, a difference of 0.27 per year after adjustment. That is a genuine difference, and it is a small one for a group whose average filtration started at 75.
Did pantoprazole cause more kidney disease or kidney injury?
Not by a statistically significant margin. The odds of new chronic kidney disease were 11% higher on pantoprazole, but the confidence interval included no effect, and acute kidney injury was 11% lower with a confidence interval that also included no effect.
Should I still have my kidney function monitored while taking PPIs?
Monitoring remains reasonable for higher risk patients, older patients, and anyone with existing kidney disease. The authors specifically note that more study is needed in people at higher risk of adverse kidney outcomes. That judgement belongs with your own clinician.
How does this compare to previous research on PPIs and the kidneys?
Earlier work was observational, showing an association between PPI use and worsening kidney function without establishing cause. This analysis used a randomized comparison, which is why its finding of a faster eGFR decline carries more weight, even though the kidney question itself was addressed after the trial concluded.
Why does the creatinine point matter?
Because eGFR is estimated from creatinine rather than measured directly, and a drug that changes how much creatinine the kidney handles can change the estimate without the kidney itself being worse.
Bottom Line
This is a post hoc analysis of the randomized COMPASS trial, in which 17,598 people received pantoprazole or placebo. Pantoprazole caused a statistically significant faster decline in kidney filtration, 1.64 versus 1.41 ml/min per 1.73 m² per year, a difference of 0.27 per year. Rates of new chronic kidney disease and acute kidney injury did not differ significantly. I treat that as a real but small signal worth watching, not a reason to stop prescribing PPIs where the indication is clear.
